{
    "nctId": "NCT06154109",
    "briefTitle": "Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial",
    "officialTitle": "Comparative Efficacy of Xiaopi Granules and Decoction in Improving Pathological Complete Response of Neoadjuvant Chemotherapy of Triple-negative Breast Cancer: a Randomized, Double-blind, Controlled Trial",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Triple Negative Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 90,
    "primaryOutcomeMeasure": "Pathological complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females aged \u226518 and \u226475 years\n* Pathological diagnosis of triple-negative breast cancer with stage II-III\n* Not having received any previous treatment for breast cancer\n* Having at least one measurable tumor\n* No distant metastases\n* ECOG score 0-2\n* Neoadjuvant chemotherapy or combination immunotherapy\n* Agree to participate in this clinical study and sign the informed consent form\n\nExclusion Criteria:\n\n* Pregnant and breastfeeding, with fertility requirements during the study period\n* Combined other malignant tumors\n* Combination of serious diseases of the heart, brain, liver, kidney, and hematopoietic system, liver function impairment, and diabetes mellitus\n* Active hepatitis B virus or hepatitis C virus infection, or human immunodeficiency virus (HIV) infection\n* Presence of factors affecting the administration and absorption of the drug\n* Allergy to the drug components of this regimen\n* A history of psychotropic substance abuse or drug use\n* The patient has other life-threatening diseases\n* Participating in other drug trials",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}